We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Point-of-Care CD4 Test Receives CE Marking

By LabMedica International staff writers
Posted on 21 Jan 2014
CE marking validation for the new test platform opens the way to highly accessible, reliable CD4 T-cell testing for HIV positive patients worldwide. More...


Zyomyx (Fremont, CA, USA) has now received the CE marking for its "MyT4" point-of-care CD4 test, intended to rapidly identify the concentration of CD4 T-lymphocytes in patients with HIV/AIDS and so to assist in decisions for treatment initiation and in drug monitoring. MyT4 is the first of an expanding line of diagnostic tests originating from Zyomyx's portfolio of proprietary platform technologies capable of moving laboratory tests for cells, proteins, and infectious agents to the point-of-care (POC) and thereby providing immediate benefits to clinicians and patients in multiple disease areas.

Zyomyx, a vertically integrated diagnostics company, developed the MyT4 test, secured its CE marking, and it expects to begin selling the product in 2014 in collaboration with Mylan, Inc. (Canonsburg, PA, USA) and the Bill & Melinda Gates Foundation (Seattle, WA, USA). As a POC solution, this quantitative test provides fast time-to-result—within minutes—and will be the only service-free test on the market, as it does not require maintenance or complex instrumentation.

"We are delighted to have met this regulatory milestone for MyT4," said Peter Wagner, President and CEO of Zyomyx; "The Zyomyx test is the fastest CD4 diagnostic on the market and delivers results that are equivalent to lab-based flow cytometry, the gold standard of CD4 testing. Zyomyx will continue to dedicate its efforts to bringing next-generation point-of-care diagnostic solutions to the market."

MyT4 is well configured to meet the needs of developing countries. For the millions of HIV/AIDS patients worldwide receiving or in need of antiretroviral therapy, a major barrier to initiating and monitoring treatment for patients is the lack of access to routine CD4 testing because flow cytometers are expensive, complex, and are only available in centralized locations, often requiring patients to wait weeks to obtain a result. Zyomyx's test will enable millions of HIV+ people to quickly receive reliable CD4 results and start or monitor lifesaving antiretroviral treatment without delay.

Related Links:

Zyomyx



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TRAcP 5b Assay
TRAcP 5b (BoneTRAP) Assay
New
Ultrasonic Cleaner
UC 300 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Pathology

view channel
Image: AI-analyzed images from the FDM microscope show platelet clumps in motion (Photo courtesy of Hirose et al CC-BY-ND)

AI Microscope Spots Deadly Blood Clots Before They Strike

Platelets are small blood cells that act as emergency responders in the body, rushing to areas of injury to help stop bleeding by forming clots. However, sometimes platelets can overreact, leading to complications.... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.